NT-0796 is under clinical development by NodThera and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NT-0796’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-0796 is under development for the treatment of inflammatory disorders. They cross the blood-brain barrier and act by targeting NLRP3 inflammasomes. It is administered through oral route.
NodThera, a subsidiary of NodThera Ltd, is a biotechnology company that discovers and develops treatments for chronic inflammation. It is investigating its lead product candidate NT-0796 against peripheral and neuroinflammatory diseases. The company is also evaluating NT-0249, a peripherally restricted NLRP3 inflammasome inhibitor to develop a low-dose therapy addressing chronic inflammatory diseases of the body. NodThera’s approach focuses on delivering advances in potency, tissue and brain penetration and chemical structural diversity. It operates with additional offices in Seattle, the US, and Cambridge, the UK. NodThera is headquartered in Lexington, Massachusetts, the US.
For a complete picture of NT-0796’s drug-specific PTSR and LoA scores, buy the report here.